The global autologous matrix-induced chondrogenesis market is expected to grow at an 8.6 percent compound annual growth rate by 2024, according to a Persistence Market Research report.
Three market insights:
1. Autologous matrix-induced chondrogenesis is a biological treatment to repair articular cartilage damage. It is designed to slow down cartilage degeneration to avoid or delay knee replacement surgery.
2. In 2016, the global market value was estimated to be $96.11 million, and is expected to increase to $186.4 million by the end of 2024.
3. Factors driving market growth include rising demand for minimally invasive procedures, increasing prevalence of bone and joint disorders and sports injuries as well as greater access.